2 COVID Vaccine Stocks That Could Trounce Pfizer and Moderna in 2021

1 min read

Pfizer (NYSE: PFE) and Moderna (NASDAQ: MRNA) will almost certainly enjoy huge revenue growth this year. Their respective coronavirus vaccines have already been given to millions of people in the U.S. and other countries. Billions of dollars will soon flow into the drugmakers’ coffers.

Both of the stocks could deliver solid gains in the coming months. However, I think there are two COVID-19 vaccine stocks that could be much-bigger winners. Here’s why Novavax (NASDAQ: NVAX) and Vaxart (NASDAQ: VXRT) could trounce both Pfizer and Moderna in 2021. 

Image source: Getty Images.

Continue reading

Leave a Reply

Your email address will not be published.

Previous Story

Raging Bull or Stock Market Crash? Here’s the Signal to Watch in 2021

Next Story

The 3 Safest Energy Dividends Right Now

Latest from Blog